You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 1, January 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Patient Education/ Health Literacy
 •Psoriasis
 •Alert me on articles by topic

Patient Education and Advocacy Groups

A Means to Better Outcomes?

Arch Dermatol. 2005;141:80-81.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Patient education programs have been rapidly expanding in health care although their benefits remain controversial.1 Multiple studies have demonstrated that patient education interventions in chronic disease can be of benefit in measured outcomes for both physician and patient. This is most evident in diseases where patient intervention can prevent hospitalization or emergency department visits, most notably in the case of asthma2-3 or diabetes mellitus,4 but also concerns the long-term outcome of other chronic diseases such as inflammatory bowel disease,5 inflammatory arthritis,6-7 and systemic lupus erythematosus.8 Well-designed trials investigating educational status and clinical outcomes in skin disease are, unfortunately, few, but there is at least 1 small study that demonstrates the benefits of direct educational intervention in patients with psoriasis.9 Despite this paucity of data, there is an assumption that patients who have a greater level of knowledge about their disease will have a more favorable disease course.

The view that . . . [Full Text of this Article]


AUTHOR INFORMATION
Kenneth B. Gordon, MD


RELATED ARTICLES

Members of the National Psoriasis Foundation: More Extensive Disease and Better Informed About Treatment Options
Tamar Nijsten, Tara Rolstad, Steven R. Feldman, and Robert S. Stern
Arch Dermatol. 2005;141(1):19-26.
ABSTRACT | FULL TEXT  

Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Alan Menter, Kenneth Gordon, Wayne Carey, Tiffani Hamilton, Scott Glazer, Ivor Caro, Nicole Li, Wayne Gulliver, and for the Efalizumab Study Group
Arch Dermatol. 2005;141(1):31-38.
ABSTRACT | FULL TEXT  

Topical Tacrolimus Ointment Combined With 6% Salicylic Acid Gel for Plaque Psoriasis Treatment
Christie L. Carroll, Jan Clarke, Fabian Camacho, Rajesh Balkrishnan, and Steven R. Feldman
Arch Dermatol. 2005;141(1):43-46.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.